Oncolix, Inc.

Calculating rank

USPTO Granted Patents = 5

% Expired Patents = 100.0

CIPO Patents = 2

EPO Patents = 4

Forward Citations = 15

Loading Chart...

2 inventors (with patents filed for the assignee):

Wen Yuan Chen (5 out of 11 patents)

Michele Lynn Scotti (1 out of 1 patent)

Wen Y Chen (5 patents)

4. Wen Yaun Chen (0 patent)

5. Wen Yaun Chen (0 patent)

6. Wen Yaun Chen (0 patent)

5 patents: Sort by Forward Citations

1. 8754035 - Compositions and methods for visualizing and eliminating cancer stem cells (2014-06-17),

2. 8754031 - Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway (2014-06-17),

3. 8648046 - Compositions and methods for visualizing and eliminating cancer stem cells (2014-02-11),

4. 8304381 - Human prolactin antagonist-angiogenesis inhibitor fusion proteins (2012-11-06),

5. 7632809 - Multimeric ligands with enhanced stability (2009-12-15),

Company Overview

Oncolix, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for women's cancers. Their leading product candidate, Prolanta, targets the overexpression of the prolactin receptor to inhibit tumor growth. With a strong commitment to improving outcomes for cancer patients, Oncolix is dedicated to advancing novel therapies through rigorous research and development.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

5 Patents

#845 in Houston, TX

#3,337 in Texas

#51,708 in US

Houston, TX, United States of America

Oncolix, Inc.

Forward Citations = 15

2 inventors:

Wen Yuan Chen (5 out of 11 patents)

Michele Lynn Scotti (1 out of 1 patent)

Wen Y Chen (5 patents)

4. Wen Yaun Chen (0 patent)

5. Wen Yaun Chen (0 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Oncolix, Inc.. Retrieved from https://idiyas.com/company/oncolix

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

2 patents (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

4 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]